Subscribe to RSS
![](/products/assets/desktop/img/oa-logo.png)
DOI: 10.1055/a-1005-6366
Comparative effectiveness of pharmacologic and endoscopic interventions for prevention of post-ERCP pancreatitis: a network meta-analysis
Publication History
submitted 07 February 2019
accepted after revision 12 August 2019
Publication Date:
08 January 2020 (online)
![](https://www.thieme-connect.de/media/10.1055-s-00025476/202001/lookinside/thumbnails/1504_10-1055-a-1005-6366-1.jpg)
Abstract
Background and study aims While several interventions may decrease risk of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis, it remains unclear whether one strategy is superior to others. The purpose of this study was to compare the effectiveness of pharmacologic and endoscopic interventions to prevent post-ERCP pancreatitis among high-risk patients.
Methods A systematic review was performed to identify randomized controlled trials from PubMed, Embase, Web of Science, and Cochrane database through May 2017. Interventions included: rectal non-steroidal anti-inflammatory drugs (NSAIDs), aggressive hydration with lactated ringerʼs (LR) solution, and pancreatic stent placement compared to placebo. Only studies with patients at high-risk for post-ERCP pancreatitis were included. Bayesian network meta-analysis was performed and relative ranking of treatments was assessed using surface under the cumulative ranking (SUCRA) probabilities.
Results We identified 29 trials, comprising 7,862 participants comparing four preventive strategies. On network meta-analysis, compared with placebo, rectal NSAIDs (B = – 0.69, 95 % CI [–1.18; – 0.21]), pancreatic stent (B = – 1.25, 95 % CI [–1.81 to –0.69]), LR (B = – 0.67, 95 % CI [–1.20 to –0.13]), and combination of LR plus rectal NSAIDs (B = – 1.58; 95 % CI [–3.0 to –0.17]), were all associated with a reduced risk of post-ERCP pancreatitis. Pancreatic stent placement had the highest SUCRA probability (0.81, 95 % CI [0.83 to 0.80]) of being ranked the best prophylactic treatment.
Conclusions Based on this network meta-analysis, pancreatic stent placement appears to be the most effective preventive strategy for post-ERCP pancreatitis in high-risk patients.
* Drs. Njei and McCarty: These authors contributed equally.
-
References
- 1 Peery AF, Dellon ES, Lund J. et al. Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology 2012; 143: 1179-1187 e1-3
- 2 Sherman S. ERCP and endoscopic sphincterotomy-induced pancreatitis. Am J Gastroenterol 1994; 89: 303-305
- 3 Silviera ML, Seamon MJ, Porshinsky B. et al. Complications related to endoscopic retrograde cholangiopancreatography: a comprehensive clinical review. J Gastrointestin Liver Dis 2009; 18: 73-82
- 4 Freeman ML, Nelson DB, Sherman S. et al. Complications of endoscopic biliary sphincterotomy. N Engl J Med 1996; 335: 909-918
- 5 Glomsaker T, Hoff G, Kvaloy JT. et al. Patterns and predictive factors of complications after endoscopic retrograde cholangiopancreatography. Br J Surg 2013; 100: 373-380
- 6 Kochar B, Akshintala VS, Afghani E. et al. Incidence, severity, and mortality of post-ERCP pancreatitis: a systematic review by using randomized, controlled trials. Gastrointest Endosc 2015; 81: 143-149 e9
- 7 Arata S, Takada T, Hirata K. et al. Post-ERCP pancreatitis. J Hepatobiliary Pancreat Sci 2010; 17: 70-78
- 8 Murray B, Carter R, Imrie C. et al. Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography. Gastroenterology 2003; 124: 1786-1791
- 9 Otsuka T, Kawazoe S, Nakashita S. et al. Low-dose rectal diclofenac for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a randomized controlled trial. J Gastroenterol 2012; 47: 912-917
- 10 Sotoudehmanesh R, Khatibian M, Kolahdoozan S. et al. Indomethacin may reduce the incidence and severity of acute pancreatitis after ERCP. Am J Gastroenterol 2007; 102: 978-983
- 11 Chang AS, Pausawasdi N, Charatcharoenwitthaya P. et al. A randomized, controlled trial of aggressive fluid hydration for the prevention of post-ERCP pancreatitis. Gastroenterol 2016; 150: S209
- 12 Buxbaum J, Yan A, Yeh K. et al. Aggressive hydration with lactated Ringer’s solution reduces pancreatitis after endoscopic retrograde cholangiopancreatography. Clin Gastroenterol Hepatol 2014; 12: 303-307 e1
- 13 Choi JH, Kim HJ, Lee BU. et al. Vigorous periprocedural hydration with lactated ringer’s solution reduces the risk of pancreatitis after retrograde cholangiopancreatography in hospitalized patients. Clin Gastroenterol Hepatol 2017; 15: 86-92 e1
- 14 Fazel A, Quadri A, Catalano MF. et al. Does a pancreatic duct stent prevent post-ERCP pancreatitis? A prospective randomized study. Gastrointest Endosc 2003; 57: 291-294
- 15 Smithline A, Silverman W, Rogers D. et al. Effect of prophylactic main pancreatic duct stenting on the incidence of biliary endoscopic sphincterotomy-induced pancreatitis in high-risk patients. Gastrointest Endosc 1993; 39: 652-657
- 16 Tarnasky PR, Palesch YY, Cunningham JT. et al. Pancreatic stenting prevents pancreatitis after biliary sphincterotomy in patients with sphincter of Oddi dysfunction. Gastroenterology 1998; 115: 1518-1524
- 17 Dobronte Z, Szepes Z, Izbeki F. et al. Is rectal indomethacin effective in preventing of post-endoscopic retrograde cholangiopancreatography pancreatitis?. World J Gastroenterol 2014; 20: 10151-10157
- 18 Hutton B, Salanti G, Chaimani A. et al. The quality of reporting methods and results in network meta-analyses: an overview of reviews and suggestions for improvement. PLoS One 2014; 9: e92508
- 19 Cipriani A, Higgins JP, Geddes JR. et al. Conceptual and technical challenges in network meta-analysis. Ann Intern Med 2013; 159: 130-137
- 20 Mills EJ, Ioannidis JP, Thorlund K. et al. How to use an article reporting a multiple treatment comparison meta-analysis. JAMA 2012; 308: 1246-1253
- 21 Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004; 23: 3105-3124
- 22 Chandrasekhara V, Khashab MA. et al. ASGE Standards of Practice Committee. Adverse events associated with ERCP. Gastrointest Endosc 2017; 85: 32-47
- 23 Testoni PA, Mariani A, Giussani A. et al. Risk factors for post-ERCP pancreatitis in high- and low-volume centers and among expert and non-expert operators: a prospective multicenter study. Am J Gastroenterol 2010; 105: 1753-1761
- 24 Chen JJ, Wang XM, Liu XQ. et al. Risk factors for post-ERCP pancreatitis: a systematic review of clinical trials with a large sample size in the past 10 years. Eur J Med Res 2014; 19: 26
- 25 Cotton PB, Eisen GM, Aabakken L. et al. A lexicon for endoscopic adverse events: report of an ASGE workshop. Gastrointest Endosc 2010; 71: 446-454
- 26 Higgins JPT, Altman DG, Sterne JAC. Cochrane Handbook for Systematic Reviews of Interventions. In: Higgins JPT, ed. The Cochrane Collaboration; 2011 Available from http://www.cochranehandbook.org
- 27 Puhan MA, Schunemann HJ, Murad MH. et al. A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ 2014; 349: g5630
- 28 Guyatt G, Oxman AD, Sultan S. et al. GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. J Clin Epidemiol 2013; 66: 151-157
- 29 DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188
- 30 White IR. Multivariate random-effects meta-regression: Updates to mvmeta. The Stata Journal 2011; 11: 255-270
- 31 Higgins JP, Thompson SG, Deeks JJ. et al. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560
- 32 Egger M, Davey SmithG, Schneider M. et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634
- 33 Review Manager (RevMan), ver. 5.3. The Cochrane Collaboration. (ed.) 2014
- 34 Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004; 23: 3105-3124
- 35 Caldwell DM, Ades AE, Higgins JP. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 2005; 331: 897-900
- 36 Chaimani A, Higgins JP, Mavridis D. et al. Graphical tools for network meta-analysis in STATA. PLoS One 2013; 8: e76654
- 37 Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol 2011; 64: 163-171
- 38 Dobronte Z, Toldy E, Mark L. et al. [Effects of rectal indomethacin in the prevention of post-ERCP acute pancreatitis]. Orv Hetil 2012; 153: 990-996
- 39 Andrade-Davila VF, Chavez-Tostado M, Davalos-Cobian C. et al. Rectal indomethacin versus placebo to reduce the incidence of pancreatitis after endoscopic retrograde cholangiopancreatography: results of a controlled clinical trial. BMC Gastroenterol 2015; 15: 85
- 40 Patai A, Solymosi N, Patai AV. Effect of rectal indomethacin for preventing post-ERCP pancreatitis depends on difficulties of cannulation: results from a randomized study with sequential biliary intubation. J Clin Gastroenterol 2015; 49: 429-437
- 41 Lua GW, Muthukaruppan R, Menon J. Can rectal diclofenac prevent post endoscopic retrograde cholangiopancreatography pancreatitis?. Dig Dis Sci 2015; 60: 3118-3123
- 42 Luo H, Zhao L, Leung J. et al. Routine pre-procedural rectal indometacin versus selective post-procedural rectal indometacin to prevent pancreatitis in patients undergoing endoscopic retrograde cholangiopancreatography: a multicentre, single-blinded, randomised controlled trial. Lancet 2016; 387: 2293-2301
- 43 Levenick JM, Gordon SR, Fadden LL. et al. Rectal indomethacin does not prevent post-ERCP pancreatitis in consecutive patients. Gastroenterology 2016; 150: 911-917 ; quiz e19.
- 44 Ucar R, Biyik M, Ucar E. et al. Rectal or intramuscular diclofenac reduces the incidence of pancreatitis afterendoscopic retrograde cholangiopancreatography. Turk J Med Sci 2016; 46: 1059-1063
- 45 Alabd M, Abdo A. Role of rectal NSAIDs in the prevention of post-ERCP pancreatitis. J Gastroenterol Hepatol 2013; 28: 495-496
- 46 Elmunzer BJ, Scheiman JM, Lehman GA. et al. A randomized trial of rectal indomethacin to prevent post-ERCP pancreatitis. N Engl J Med 2012; 366: 1414-1422
- 47 Chuankrerkkul P. Aggressive lactated Ringer’s solution for prevention of post ERCP pancreatitis (preliminary data of a prospective randomized trial). Gastrointest Endosc 2015; 81: AB410-AB411
- 48 Rosa B, Carvalho PB, De Castro FD. et al. Impact of intensive hydration on the incidence of post-ERCP pancreatitis: doubleblinded randomized controlled trial. Gastrointest Endosc 2016; 83: AB250
- 49 Shaygan-Nejad A, Masjedizadeh AR, Ghavidel A. et al. Aggressive hydration with Lactated Ringer’s solution as the prophylactic intervention for postendoscopic retrograde cholangiopancreatography pancreatitis: A randomized controlled double-blind clinical trial. J Res Med Sci 2015; 20: 838-843
- 50 NorthShore University Health System, Medical College of Wisconsin. et al. High volume lactated Ringer’s solution and pancreatitis. National Library of Medicine (US); 2016 Available at: https://clinicaltrials.gov/show/NCT02050048 [Accessed December 21, 2016.]
- 51 Mok SRS, Ho HC, Shah P. et al. Lactated Ringer’s solution in combination with rectal indomethacin for prevention of post-ERCP pancreatitis and readmission: a prospective randomized, double-blinded, placebo-controlled trial. Gastrointest Endosc 2017; 85: 1005-1013
- 52 Harewood GC, Pochron NL, Gostout CJ. Prospective, randomized, controlled trial of prophylactic pancreatic stent placement for endoscopic snare excision of the duodenal ampulla. Gastrointest Endosc 2005; 62: 367-370
- 53 Sofuni A, Maguchi H, Itoi T. et al. Prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis by an endoscopic pancreatic spontaneous dislodgement stent. Clin Gastroenterol Hepatol 2007; 5: 1339-1346
- 54 Pan XP, Dang T, Meng XM. et al. Clinical study on the prevention of post-ERCP pancreatitis by pancreatic duct stenting. Cell Biochem Biophys 2011; 61: 473-479
- 55 Lee TH, Moon JH, Choi HJ. et al. Prophylactic temporary 3F pancreatic duct stent to prevent post-ERCP pancreatitis in patients with a difficult biliary cannulation: a multicenter, prospective, randomized study. Gastrointest Endosc 2012; 76: 578-585
- 56 Kawaguchi Y, Ogawa M, Omata F. et al. Randomized controlled trial of pancreatic stenting to prevent pancreatitis after endoscopic retrograde cholangiopancreatography. World J Gastroenterol 2012; 18: 1635-1641
- 57 Cha SW, Leung WD, Lehman GA. et al. Does leaving a main pancreatic duct stent in place reduce the incidence of precut biliary sphincterotomy-associated pancreatitis? A randomized, prospective study. Gastrointest Endosc 2013; 77: 209-216
- 58 Olsson G, Lubbe J, Arnelo U. et al. The impact of prophylactic pancreatic stenting on post-ERCP pancreatitis: A nationwide, register-based study. United European Gastroenterol J 2017; 5: 111-1118
- 59 Dumonceau JM, Andriulli A, Elmunzer BJ. et al. Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014. Endoscopy 2014; 46: 799-815
- 60 Yokoe M, Takada T, Mayumi T. et al. Japanese guidelines for the management of acute pancreatitis: Japanese Guidelines 2015. J Hepatobiliary Pancreat Sci 2015; 22: 405-432
- 61 Akbar A, Abu Dayyeh BK. et al. Rectal nonsteroidal anti-inflammatory drugs are superior to pancreatic duct stents in preventing pancreatitis after endoscopic retrograde cholangiopancreatography: a network meta-analysis. Clin Gastroenterol Hepatol 2013; 11: 778-783
- 62 Medical University of South Carolina. Stent vs. indomethacin for preventing post-ERCP pancreatitis (SVI). National Library of Medicine (US); 2018 Available at: https://clinicaltrials.gov/ct2/show/NCT02476279?cond=stent+vs.+indomethacin+for+preventing+post-ercp+pancreatitis&rank=1 [Accessed March 21, 2018.]
- 63 Cote GA. The end of prophylactic pancreatic duct stents? Proceed with caution and courage. Clin Gastroenterol Hepatol 2014; 12: 528
- 64 Cheng CL, Sherman S, Watkins JL. et al. Risk factors for post-ERCP pancreatitis: a prospective multicenter study. Am J Gastroenterol 2006; 101: 139-147
- 65 Cotton PB, Garrow DA, Gallagher J. et al. Risk factors for complications after ERCP: a multivariate analysis of 11,497 procedures over 12 years. Gastrointest Endosc 2009; 70: 80-88
- 66 Freeman ML, DiSario JA, Nelson DB. et al. Risk factors for post-ERCP pancreatitis: a prospective, multicenter study. Gastrointest Endosc 2001; 54: 425-434